Abstract 1652
Background
In cancer patients undergoing myelosuppressive chemotherapy, granulocyte colony-stimulating factor (G-CSF) reduces the risk of neutropenic complications and decreases need for dose reductions,1 allowing potential improvement of survival. A recent meta-analysis found that those receiving G-CSF have significantly improved overall survival (OS) versus those who do not.2 Deemed a “gold standard” approach for estimating probabilities of survival for time-to-event data,3 Kaplan-Meier (KM) estimates are a non-parametric method with no underlying distributional assumptions, allowing comparison between studies. Meta-analysis methods based on KM curves have been proposed.4,5 We present a new approach of pooling KM curves, improving their accuracy in assessing survival probabilities.
Methods
Our new approach pinpoints specific coordinates on KM curves using web-based digital graphics data extraction tools. When the amount of at risk patients during a specific time period is known, the number of patients experiencing events can be calculated, or if unknown, imputed by “borrowing” event percentages from a study with a similar KM survival profile. Using minimum squared distances between pairs, the similarity between two KM curves can be determined. Reconstructed event times can be used for meta-analyses, using fixed or random effect modeling with weights for each study.
Results
This approach was applied to 70 reports of OS in cancer patients receiving chemotherapy with or without G-CSF prophylaxis, including recent meta-analysis data.2 Preliminary results are in line with published data. Supporting reports of better survival in patients receiving G-CSF, the new approach provides synthesized KM curves, allowing comparisons of survival probabilities between treatments at any given time points.
Conclusions
Our preliminary results support findings of significantly improved OS in cancer patients receiving G-CSF. References: 1. Aapro et al. Support Care Cancer 2010;18:529–41. 2. Lyman et al. Blood 2017:130;3424. 3. Land et al. Procedia Comput Sci. 2011;6:267–72. 4. Parmar et al. Statist Med. 1998; 17:2815–34. 5. Tierney et al. Trials 2007;8:16.
Clinical trial identification
Legal entity responsible for the study
Hexal AG, Holzkirchen, Germany.
Funding
Hexal AG, Holzkirchen, Germany.
Editorial Acknowledgement
Terri Penfold, Spirit Medical Communications.
Disclosure
A. Krendyukov, L. Yau: Employee: Hexal AG.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract